TABLE 6.
The top ten frequently cited papers.
| No | First author | Journal | Year | Citations | Citation frequency per year | Descriptions |
|---|---|---|---|---|---|---|
| 1 | Riad Salem | GASTROENTEROLOGY | 2010 | 741 | 49.40 | This single-centre, prospective, and longitudinal study reported the long-term safety and response rates of TheraSpheres in TARE-related studies for HCC. The survival outcomes of TARE and TACE were similar. The main survival predictors were liver function and PVT. Moreover, patients with Child-Pugh A disease, with or without PVT, benefited most from this treatment |
| 2 | Valérie Vilgrain | LANCET ONCOL | 2017 | 534 | 66.75 | SARAH was a multi-centre, open-label, and randomized controlled phase 3 trial comparing the efficacy and safety of SIR-Sphere SIRT with sorafenib. No significant difference was observed in overall survival between the two groups with locally advanced or intermediate-stage HCC after an unsuccessful TACE. However, the SIRT group exhibited enhanced tumour response, quality of life, and safety than the sorafenib group |
| 3 | Bruno Sangro | HEPATOLOGY | 2011 | 488 | 34.86 | This retrospective multi-centre analysis evaluated the survival prognostic factors after SIR-Sphere TARE for HCC. Liver function and Child-Pugh scores were significant survival predictors. Moreover, TARE might achieve survival benefits across different tumour stages, advanced disease patients, and those with few treatment options |
| 4 | Riad Salem | GASTROENTEROLOGY | 2011 | 478 | 34.14 | This retrospective study compared the efficacy of TACE with TheraSphere TARE in HCC patients. Both these therapies provided similar survival outcomes; however, TARE was better tolerated than TACE, with fewer toxicities and without any inpatient hospitalization. The study indicated that a randomized trial with >1000 patients can establish the equivalence of survival times between patients treated with TARE and TACE. |
| 5 | Laura M Kulik | HEPATOLOGY | 2008 | 458 | 26.94 | This prospective phase 2 cohort study revealed the safety profile and efficacy of TheraSphere TARE for unresectable HCC, with or without PVT. Thus, TARE is a safe procedure with favourable tumour response rates for HCC patients complicated by branch/lobar PVT. |
| 6 | R J Lewandowski | AM J TRANSPLANT | 2009 | 427 | 26.69 | This single-centre study compared the downstaging efficacy of TACE and TARE. Although both treatments significantly reduced the tumour size from baseline, TheraSphere TARE outperformed TACE for downstaging HCC from UNOS T3 to T2 |
| 7 | Pierce K H Chow | J CLIN ONCOL | 2018 | 415 | 59.29 | This multi-centre, open-label, phase 3 trial compared the efficacy of SIR-Sphere TARE and sorafenib in locally advanced HCC patients. Overall survival was similar between TARE and sorafenib in locally advanced HCC patients. However, TARE displayed a better tumour response rate and fewer adverse events than sorafenib |
| 8 | Riad Salem | GASTROENTEROLOGY | 2016 | 403 | 44.78 | This randomized, phase 2 study compared the effectiveness of cTACE and TheraSphere TARE in HCC patients of BCLC stages A or B. The results showed that TARE provided a significantly longer time to progression and reduced transplant waitlist dropout rates |
| 9 | Vincenzo Mazzaferro | HEPATOLOGY | 2013 | 363 | 30.25 | This prospective phase 2 study evaluated the efficacy and safety of TheraSphere TARE in intermediate and advanced HCC. The study suggested that TARE was effective in intermediate to advanced HCC cases, particularly in PVT patients |
| 10 | Philip Hilgard | HEPATOLOGY | 2010 | 340 | 22.67 | This single-centre observational study evaluated the efficacy of TheraSphere TARE in European advanced HCC patients and showed that TARE was a safe and effective treatment for European HCC patients and could be used in impaired liver function patients |